Sign In
Buy NAVB
$0.0001
+0 (+0%)
At Close: Dec 30, 2025
Mid-Day Market Update: LiveRamp Surges Following Q4 Results; Syndax Pharmaceuticals Shares Plummet
04:39pm, Friday, 22'nd May 2020Mid-Morning Market Update: Markets Fall; Alibaba Earnings Beat Estimates
02:12pm, Friday, 22'nd May 2020Navidea Biopharmaceuticals stock rockets toward 13-month high on heavy volume after update trial data
12:35pm, Friday, 22'nd May 2020
Shares of Navidea Biopharmaceuticals Inc. more than doubled in very active premarket trading Friday, after the company provided upbeat data on an ongoing phase 2 trial of its treatment for rheumatoid
The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray
11:10am, Friday, 22'nd May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 21) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * A
The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray
12:00am, Friday, 22'nd May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 21)
ADC Therapeutics SA (NYSE:...
Navidea Biopharmaceuticals Announces Positive Results of Second Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis
08:30pm, Thursday, 21'st May 2020
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to ann
Navidea Biopharmaceuticals Announces Positive Results of Second Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis
12:00am, Thursday, 21'st May 2020
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnosti
Edited Transcript of NAVB earnings conference call or presentation 14-May-20 9:00pm GMT
07:29am, Friday, 15'th May 2020
Q1 2020 Navidea Biopharmaceuticals Inc Earnings Call
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q1 2020 Results - Earnings Call Transcript
03:09am, Friday, 15'th May 2020
Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) Q1 2020 Results Earnings Conference Call May 14, 2020, 5:00 pm ET Company Participants Jed Latkin - Chief Execut
Navidea Biopharmaceuticals Reports First Quarter 2020 Financial Results
08:01pm, Thursday, 14'th May 2020
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced i
Navidea Biopharmaceuticals Reports First Quarter 2020 Financial Results
12:00am, Thursday, 14'th May 2020
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnosti
Navidea Biopharmaceuticals Regains Commercialization and Distributions Rights in Europe for LYMPHOSEEK®
11:30am, Monday, 11'th May 2020
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to ann
Navidea Biopharmaceuticals Regains Commercialization and Distributions Rights in Europe for LYMPHOSEEK®
12:00am, Monday, 11'th May 2020
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnosti
